Economic impact of eyedrop cost in glaucoma treatment;Impacto econômico do custo de colírios no tratamento do glaucoma

Arquivos Brasileiros de Oftalmologia

Volumn 68, Issue 1, 2005, Pages 79-84

  Stillitano, Iane Gonçalves ^a,e   De Lima, Manoel Gonçalves ^b   Ribeiro, Marco Polo ^c   Cabral, Juliana ^d   Brandt, Carlos Teixeira ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Clínica de Olhos Dr Manoel Gonçalves   (Brazil)

^c WILLS EYE HOSPITAL   (United States)

^d Hospital de Olhos Leiria de Andrade CE   (Portugal)

^e NONE   (Brazil)

Author keywords

Drug costs; Expenditures, drugs; Glaucoma economics; Ophthalmic solutions economics

Indexed keywords

APRACLONIDINE; B TABLOCK; BETAXOLOL; BIMATOPROST; BRINZOLAMIDE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; GLAUTIMOL; LATANOPROST; LATANOPROST PLUS TIMOLOL MALEATE; NYOLOL; PILOCAN; PILOCARPINE; TIMOLOL MALEATE; TIMOPTOL XE; TRAVOPROST;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC ASPECT; GLAUCOMA; HEALTH CARE COST; HUMAN; SALARY;

EID: 28244453339     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492005000100014     Document Type: Article

References (23)

1. Smith AF, Smith JG. The economic burden of global blindness: a price too high! Br J Ophthalmol. 1996;80(4):276-7.
2. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma. 2002;11(6):531-9.
3. Czechowicz-Janicka K, Orlewska E, Tobota Z, Anielska E, Dyczkowska A. Analysis of glaucoma therapy costs in Poland. I. Population of the Mazovian District. Klin Oczna. 2000;102(6):417-22.
4. Pedroso E, Carvalho Jr ES, Paranhos Jr A, Prata Jr JA, Mello PAA. Custo real do tratamento do glaucoma para o paciente. Arq Bras Oftalmol. 1999;62 (6):677-82.
5. Vold SD, Wiggins DA, Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma. 2000;99(3):150-3.
6. Fiscella RG, Geller JE, Gryz LL, Wilensky J, Viana M. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol. 1999;128(4):426-33.
7. Amaral Filho JM, Moreira RAR, Silva EMS, Vasconcelos JP, Rocha EM, Costa VP, et al. Custo mensal de medicações antiglaucomatosas no Brasil. Arq Bras Oftalmol. 1999;62(2):123-6.
8. Louzada NT. Os médicos, os planos de saúde e a economia. Análise circunstancial. In: Centurion V. As bases da administraç ão em oftalmologia. Rio de Janeiro: Cultura médica: 2001. p.265-77.
9. Sherwood MB, Garcia-Siekavizza AG, Meltzer MI, Hebert A, Burns AF, McGorray S. Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology. 1998;105(3):561-6.
10. Commented in: Ophthalmology. 1999;106(3):440.
11. Perfetti S, Varotto A, Massagrandi S, Pagliani F, Bonomi F. Glaucoma and quality of life. Acta Ophthalmol Scand. 1998;Suppl(227):52.
12. Silva LMS, Vasconcelos JPC, Temporini ER, Costa VP, Kara-José N. Tratamento clínico do glaucoma em um hospital universitário: custo mensal e impacto na renda familiar. Arq Bras Oftalmol. 2002;65(3):123-6.
13. Ikeda H, Sato E, Kitaura T, Fukuchi H, Kimura Y, Kihira K. Daily cost of ophthalmic solutions for treating glaucoma in Japan. Jpn J Ophthalmol. 2001;45(1):99-102.
14. Stewart WC, Sine C, Cate E, Minno GE, Hunt HH. Daily cost of β-Adrenergic blocker therapy. Arch Ophthalmol. 1997;115(7):853-6.
15. Commented in: Arch Ophthalmol. 1997;115(7):914.
16. Kobelt G, Jönsson E. Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care. 1999;15(1):207-19.
17. Stewart WC, Hudgins AC, Pruitt CA, Sine C. Daily cost of newer glaucoma agents. J Ocul Pharmacol Ther. 1999;15(5):379-88.
18. Lederer CM, Harold RF. Drop size of commercial glaucoma medications. Am J Ophthalmol. 1986;101(6):691-4.
19. Brown RH, Hotchkiss ME, Davis EB. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am J Ophthalmol. 1985;99(4):460-4.
20. Stillitano IG, Tenório A, Cardoso G, Ribeiro MP, Figueiroa JN. Custo do tratamento de drogas antiglaucomatosas: latanoprost, travoprost, bimatoprost e unoprostona isopropílica. Arq Bras Oftalmol. 2003;66(6):859-64.
21. Kobelt G, Jönsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol. 1998;236(11):811-21.
22. Kass MA, Gordon M. The effect of a generic drug law on the retail cost of antiglaucoma medications. Am J Ophthalmol. 1981;92(2):273-8.
23. Nishijima M. Estudo de avaliação do impacto dos genéricos sobre a economia. Ciência Hoje On-line [periódico na Internet], 2003. [citado 2003 mai 11]. Disponível em: www.uol.com.br/cienciahoje/chdia/n833.htm